Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Young-Onset Colon Cancer and Recurrence Risk by Gene Expression.

Journal of the National Cancer Institute - 1 Nov 2020

Chang George J, You Y Nancy Y, Russell Christy A, Tierno Marni B, Turner Michelle, Bennett John P, Lau Anna, Hochster Howard S

Abstract excerpt

The incidence and mortality from colorectal cancer in younger adults (younger than 55 years) is increasing. We reviewed the complete database of a gene-expression test, Oncotype DX Colon Recurrence Score test, to determine age-related differences in recurrence score (RS) and single-gene results (7 cancer-related of the 12-gene assay). We included 20 478 stage II and III A and B colon cancer patients submitted to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Age Factors
Share to Colonic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression

Share to Gene Expression Profiling

Share to Genetic Predisposition to Disease

Share to Neoplasm Recurrence, Local

Share to Neoplasm Staging

Source

Open in PubMed Open full text

Identifiers

PMID: 32040172
DOI: 10.1093/jnci/djaa019
PMCID: PMC7669228

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Young-Onset Colon Cancer and Recurrence Risk by Gene Expression.PMID 32040172Read ↗

12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study.Semantic proximity Read ↗

Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.Semantic proximity Read ↗

Recurrence-Associated Long Non-coding RNA Signature for Determining the Risk of Recurrence in Patients with Colon CancerSemantic proximity Read ↗

Common cancer stem cell gene variants predict colon cancer recurrence.Semantic proximity Read ↗

Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy.Semantic proximity Read ↗

Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX®Colon Cancer AssaySemantic proximity Read ↗

Development of a Clinically Feasible Molecular Assay to Predict Recurrence of Stage II Colon CancerSemantic proximity Read ↗

Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease AssaySemantic proximity Read ↗

Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.Semantic proximity Read ↗

Association between antibiotic use during early life and early-onset colorectal cancer risk overall and according to polygenic risk and FUT2 genotypes.Semantic proximity Read ↗

Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus LeucovorinSemantic proximity Read ↗

CLC and IFNAR1 are differentially expressed and a global immunity score is distinct between early- and late-onset colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.